A fluorescent immunochromatographic release agent and its application
By using the combination of Tetronic 1307 and polyoxyethylene lauryl ether in fluorescent immunochromatography reagents, combining electrolytes and preservatives, the stability and release rate of the fluorescent immunochromatography reagent storage solution is solved, and higher detection is achieved Accuracy and longer shelf life reduce costs.
Patent Information
- Application Number
- CN202211659253.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-22
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2042-12-22
AI Technical Summary
The existing fluorescent immunochromatography reagent storage solution has insufficient pH value and complex stability, resulting in inaccurate detection results and high storage costs.
Using the combination of Tetronic 1307 and polyoxyethylene lauryl ether, combined with the appropriate pH value (7.2~8.2), and adding electrolytes, protective agents and preservatives to form a fluorescent immunochromatography release agent to improve the Stability and release rate of fluorescent microsphere complexes.
It significantly improves the stability and detection speed of fluorescent microsphere complexes, improves the sensitivity and accuracy of detection, and extends the shelf life of the reagent to 3 years, reducing storage and use costs.
Smart Images

Figure CN116027024B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of biological detection, and in particular to a fluorescent immunochromatography release agent and application thereof. Background Art
[0002] Fluorescence immunoassay technology has the advantages of strong specificity, high sensitivity, and good practicality. Therefore, it is widely used to measure low-content bioactive substances, such as proteins (enzymes, receptors, antibodies), hormones (steroids, thyroid hormones, phthaloyl hormones), etc. At present, fluorescence immunochromatography technology has been widely used in food analysis, infectious disease detection, acute cardiovascular and cerebrovascular disease detection, diabetes detection and other fields. Fluorescence immunochromatography is divided into dry fluorescence immunochromatography and wet fluorescence immunochromatography. Among them, dry fluorescence immunochromatography usually uses a gold sprayer to spray the labeled antibody-fluorescent microsphere complex solution onto a glass cellulose membrane (or polyester cellulose membrane) after the fluorescent microspheres are directly labeled with antibodies (or antigens), and freeze drying or heated air drying is used to remove excess water to obtain a dry fluorescent binding pad, which is then combined with NC membranes and other materials to form a detection reagent card. Therefore, the fluorescent microsphere preservation solution has a direct impact on the final analytical performance and stability of the reagent. If the reagent is unstable, it is easy to degrade or decay, resulting in inaccurate reagent detection, while increasing the storage cost and use cost of the reagent.
[0003] At present, there is no mature fluorescent complex preservation solution for various fluorescent reagents. The commonly used preservation solution is generally Tris buffer with BSA and an appropriate amount of antibacterial agent added. The shelf life is short, and there are problems such as incomplete release or too long release time during use, which have an adverse effect on the accuracy of the test results. Summary of the invention
[0004] The present invention provides a fluorescent immunochromatography release agent, comprising:
[0005] 0.05% to 1.5% Tetronic 1307 and 0.1 to 10 g / L polyoxyethylene lauryl ether;
[0006] The pH of the fluorescent immunochromatography release agent is 7.2-8.2.
[0007] After a large number of screening and compounding, the present invention found that the combination of Tetronic 1307 and polyoxyethylene lauryl ether at the above concentration under a pH environment of 7.2-8.2 can significantly improve the stability of the fluorescent microsphere complex, accelerate the release rate of the fluorescent microspheres, and improve the detection speed, sensitivity and accuracy of fluorescent immunochromatography.
[0008] As a preferred embodiment of the present invention, the mass concentration of Tetronic 1307 is 0.1% to 1.0%; and / or the concentration of polyoxyethylene lauryl ether is 0.1 to 0.5 g / L.
[0009] At the above concentration, the stability of the fluorescent microsphere complex can be further improved, and the detection speed can be further accelerated, thereby improving the sensitivity and accuracy of the detection.
[0010] As a preferred embodiment of the present invention, the fluorescent immunochromatographic release agent further comprises: 0.5-1.5 g / L of electrolyte.
[0011] As a preferred embodiment of the present invention, the electrolyte is a sodium salt, preferably sodium chloride.
[0012] In the presence of sodium salt electrolyte, the compounding effect of Tetronic 1307 and polyoxyethylene lauryl ether can be promoted, further improving the stability of the reagent.
[0013] As a preferred embodiment of the present invention, the fluorescent immunochromatographic release agent further comprises: a protective agent with a mass concentration of 0.05-2%.
[0014] As a preferred embodiment of the present invention, the protective agent is at least one of BSA, gelatin, sucrose, trehalose, sodium caseinate, arginine, PVP, and sorbitol.
[0015] As a preferred embodiment of the present invention, the fluorescent immunochromatography release agent further comprises: 0.4-0.6 g / L of preservative.
[0016] As a preferred embodiment of the present invention, the preservative is Proclin preservative, preferably Proclin300.
[0017] As a preferred embodiment of the present invention, the fluorescent immunochromatographic release agent further comprises: 10 to 50 mmol / L buffer;
[0018] The buffer is Tris buffer, PB buffer, Hepes buffer, MES buffer or borate buffer.
[0019] As a more preferred embodiment of the present invention, the fluorescent immunochromatography release agent comprises:
[0020] The mass concentration of the release agent is 0.1% to 1.0% Tetronic 1307, 0.1 to 0.5 g / L polyoxyethylene lauryl ether, 0.5 to 1.5 g / L sodium chloride, 0.05 to 2% BSA, 0.4 to 0.6 g / L Proclin 300, and 10 to 50 mmol / L Hepes buffer; and the pH value of the fluorescent immunochromatography release agent is 7.2-8.2.
[0021] Furthermore, the present invention provides use of the fluorescent immunochromatography releaser in any of the above embodiments in fluorescent immunochromatography.
[0022] As a preferred embodiment of the present invention, the present invention provides use of the fluorescent immunochromatography release agent in any of the above embodiments in a dry fluorescent immunochromatography reagent storage solution.
[0023] As a preferred embodiment of the present invention, the application includes:
[0024] The fluorescent immunochromatographic release agent is used as a storage solution and mixed with the protein-fluorescent microsphere complex, and then the mixed solution is coated on the conjugate pad and dried to form a fluorescent detection reagent card.
[0025] Compared with the prior art, the present invention has the following beneficial effects:
[0026] The fluorescent immunochromatographic releaser of the present invention can accelerate the release rate of fluorescent microspheres and save detection time. Moreover, the raw materials of the fluorescent immunochromatographic releaser of the present invention are easily available and have low cost, and can well protect the stability of the microsphere complex. Under this system, the reagent can be stored at room temperature for up to 3 years, thereby significantly improving the stability of the reagent, the sensitivity and accuracy of clinical detection results. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 It is a schematic diagram of the linear range detection results of detecting HbA1c in a sample using the kit provided by the present invention.
[0028] Figure 2 It is a schematic diagram of the correlation detection results of detecting HbA1c in a sample using the kit provided by the present invention. DETAILED DESCRIPTION
[0029] In order to make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be described clearly and completely below. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0030] If no specific techniques or conditions are specified in the examples, all are carried out according to conventional methods or the techniques or conditions described in the literature in the field, or according to the product instructions. If no manufacturer is specified for the reagents and instruments used, all are conventional products that can be purchased through regular channels.
[0031] The percentages in the following examples all represent mass concentrations.
[0032] Example 1
[0033] This embodiment provides a fluorescent immunochromatography release agent, comprising:
[0034] Tetronic 1307 0.5%, sodium chloride 0.85 g / L, polyoxyethylene lauryl ether 0.1 g / L, Proclin 3000.5 g / L, BSA 1%, 50 mmol / L Hepes buffer, the solution pH is 7.8.
[0035] Example 2
[0036] This embodiment provides a fluorescent immunochromatography release agent, comprising:
[0037] Tetronic 1307 0.1%, sodium chloride 0.85 g / L g / L, polyoxyethylene lauryl ether 0.2 g / L, Proclin 3000.5 g / L, BSA 1%, 40 mmol / L Tris buffer, the solution pH is 7.4.
[0038] Example 3
[0039] This embodiment provides a fluorescent immunochromatography release agent, comprising:
[0040] Tetronic 1307 0.1%, sodium chloride 0.85 g / L, polyoxyethylene lauryl ether 0.5 g / L, Proclin 3000.5 g / L, BSA 1%, 30 mmol / L Tris buffer, the pH value of the solution is 7.4.
[0041] Comparative Example 1
[0042] This comparative example provides a fluorescent immunochromatographic release agent, which is different from Example 1 only in that Tetronic 1307 is replaced by Tween-20.
[0043] Comparative Example 2
[0044] This comparative example provides a fluorescent immunochromatographic release agent, which is different from Example 1 only in that Tetronic 1307 is replaced by span-40.
[0045] Comparative Example 3
[0046] This comparative example provides a fluorescent immunochromatographic release agent, which is different from Example 1 only in that Tetronic 1307 is not added.
[0047] Comparative Example 4
[0048] This comparative example provides a fluorescent immunochromatographic release agent, which is different from Example 1 in that the pH value of the solution is 7.0.
[0049] Test Example 1
[0050] This test example provides the use of the fluorescent immunochromatography release agent of the above-mentioned Example 1 in fluorescent immunochromatography, which specifically includes the following steps:
[0051] The fluorescent microsphere complex labeled with glycated hemoglobin (HbA1c) antibody was ultrasonically dispersed in the fluorescent immunochromatographic release agent of Example 1, sprayed onto glass cellulose using a gold sprayer, and dried to prepare an HbA1c fluorescent binding pad.
[0052] HbA1c antibody and goat anti-mouse IgG antibody were diluted to 1 mg / mL with PBS solution containing 0.06% trehalose, respectively, and sprayed on the nitrocellulose membrane at a spray volume of 0.8 μL / cm to form HbA1c detection line and quality control line, respectively, which are analytical membranes. After drying, the sample pad, conjugate pad, analytical membrane and absorbent pad were successively overlapped and pasted on the PVC base plate and partially overlapped, and cut into paper strips with a width of 4 mm to obtain the HbA1c detection reagent card.
[0053] Performance Testing
[0054] Sample detection: Take 10μL of sample and add it to 80μL of sample diluent. After mixing evenly, pipette 80μL and add it to the sample well of the HbA1c test reagent card. After reacting for 8 minutes, detect it with a fluorescence analyzer.
[0055] (1) Linearity evaluation
[0056] The HbA1c high-value blood sample was diluted with physiological saline at a certain ratio, and the test kit was tested with this as the sample. Each dilution was tested 3 times, and the mean (yi) of the test results was calculated. The linear regression equation was calculated with the dilution (xi) as the independent variable and the measured mean (yi) as the dependent variable.
[0057] The calculation results of the measured samples are shown in Table 1 and Figure 1 shown.
[0058] Table 1 Sample test results
[0059] Dilution multiple Mean Theoretical value Absolute Deviation Relative deviation 0.1 1.67% 1.50% 0.17% 11.33% 0.2 3.24% 3.00% 0.24% 8.00% 0.4 5.68% 6.00% -0.32% -5.33% 0.6 9.18% 9.00% 0.18% 2.00% 0.8 12.64% 12.00% 0.64% 5.33% 1 14.68% 15.00% -0.32% -2.13%
[0060] (2) Repeatability
[0061] The high and low concentration samples were tested repeatedly, and each level was tested 10 times, and the average value and coefficient of variation (CV) were calculated. The test results are shown in Table 2.
[0062] Table 2 Repeatability test results
[0063]
[0064]
[0065] (3) Relevance
[0066] The reagent of the present invention and the similar reagent on the market were used to measure 100 blood samples of different concentrations, and the correlation coefficient (r) of the two sets of data was calculated. The results of the serum sample calculation are shown in Figure 2 shown.
[0067] Test Example 2
[0068] The fluorescent immunochromatographic release agents in Examples 2 to 3 were tested using the above method, and the results are as follows:
[0069] The calculation results of the samples measured in Example 2 and Example 3 are shown in Table 3 and Table 4.
[0070] Table 3 Example 2 Sample Test Results
[0071] Dilution multiple Mean Theoretical value Absolute Deviation Relative deviation 0.1 1.37% 1.50% -0.13% -8.67% 0.2 2.80% 3.00% -0.20% -6.67% 0.4 5.80% 6.00% -0.20% -3.33% 0.6 9.35% 9.00% 0.35% 3.89% 0.8 12.42% 12.00% 0.42% 3.50% 1 15.70% 15.00% 0.70% 4.67%
[0072] Table 4 Example 3 Sample Test Results
[0073]
[0074]
[0075] Repeatability
[0076] The high and low concentration samples were tested repeatedly, and each level was tested 10 times, and the average value and coefficient of variation (CV) were calculated. The test results of Example 2 and Example 3 are shown in Table 5.
[0077] Table 5 Repeatability test results
[0078]
[0079] Test Example 3
[0080] The fluorescent immunochromatographic release agents in Comparative Examples 1 and 2 were tested using the above method, and the results were as follows:
[0081] The calculation results of the samples measured in Comparative Examples 1 and 2 are shown in Tables 6 and 7.
[0082] Table 6 Comparative Example 1 Sample Test Results
[0083] Dilution multiple Mean Theoretical value Absolute Deviation Relative deviation 0.1 1.15% 1.50% -0.35% -23.33% 0.2 2.21% 3.00% -0.79% -26.33% 0.4 4.90% 6.00% -1.10% -18.33% 0.6 9.35% 9.00% 0.35% 3.89% 0.8 12.63% 12.00% 0.63% 5.25% 1 15.44% 15.00% 0.44% 2.93%
[0084] Table 7 Comparative Example 2 Sample Test Results
[0085] Dilution multiple Mean Theoretical value Absolute Deviation Relative deviation 0.1 1.03% 1.50% -0.47% -31.39% 0.2 2.01% 3.00% -0.99% -32.95% 0.4 4.76% 6.00% -1.24% -20.75% 0.6 8.44% 9.00% -0.56% -6.23% 0.8 12.34% 12.00% 0.34% 2.84% 1 15.25% 15.00% 0.25% 1.64%
[0086] Repeatability
[0087] The high and low concentration samples were tested repeatedly, and each level was tested 10 times, and the average value and coefficient of variation (CV) were calculated. The results of comparative examples 1 and 2 are shown in Table 8.
[0088] Table 8 Repeatability test results
[0089]
[0090]
[0091] Test Example 4
[0092] This test example tests the stability and reaction time of the fluorescent immunochromatographic release agent in the above examples and comparative examples.
[0093] (4) Stability test
[0094] The test method is: prepare a batch of products, test the quality control product once on day 0, and store the rest at room temperature in the warehouse. Test the quality control product of the same concentration at 1 month, 3 months, 5 months, 10 months, 15 months, 20 months, 30 months, and 36 months, record the test values, calculate the deviation between the values at different times and the values on day 0, and fill in the table below. The results are shown in Table 9.
[0095] Table 9 Stability test results
[0096] Detection time January March May October 15 months 20th 30 months 36 months Example 1 0.35% 3.19% 2.28% 0.47% 0.76% 1.04% 1.11% 3.54% Example 2 0.38% 2.89% 2.33% 1.99% 0.87% 1.78% 2.07% 2.49% Example 3 0.88% 2.52% 2.39% 1.80% 1.62% 1.81% 2.12% 1.22% Comparative Example 1 1.57% 2.45% 5.26% 6.95% 9.05% 15.33% 18.04% 25.90% Comparative Example 2 1.82% 2.63% 4.38% 5.42% 9.99% 14.33% 19.40% 22.88% Comparative Example 3 1.04% 2.11% 3.54% 6.70% 11.88% 16.35% 21.10% 23.28% Comparative Example 4 2.27% 0.78% 4.94% 5.31% 10.43% 13.26% 16.77% 18.36%
[0097] (5) Reaction time test
[0098] The test method is: place the prepared product test card flat on the laboratory table, start timing after the sample is added, and record the test values at 1min, 3min, 5min, 8min, 10min, 13min, and 15min after the sample is added. The results are shown in Table 10.
[0099] Table 10 Reaction time test results
[0100] Detection time 1min 3min 5min 8min 10min 13min 15min Example 1 3.48% 4.46% 5.59% 6.65% 6.63% 6.67% 6.65% Example 2 3.20% 5.09% 5.75% 6.56% 6.62% 6.63% 6.64% Example 3 3.27% 4.24% 5.38% 6.40% 6.42% 6.44% 6.45% Comparative Example 1 1.42% 2.43% 4.05% 5.11% 5.72% 5.97% 6.24% Comparative Example 2 1.44% 2.69% 3.77% 5.24% 5.80% 6.19% 6.89% Comparative Example 3 1.14% 2.21% 3.51% 4.94% 5.11% 5.59% 6.62% Comparative Example 4 1.31% 3.43% 4.26% 4.77% 5.36% 6.17% 6.36%
[0101] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. A fluorescent immunochromatography release agent, characterized in that: It is composed of the following components: The mass concentrations are 0.1% Tetronic 1307, 0.85g / L sodium chloride, 0.5g / L polyoxyethylene lauryl ether, 0.5g / L Proclin 300, 1% BSA and 30mmol / L Tris buffer, and the pH value of the fluorescent immunochromatography releaser is 7.
4.
2. Use of the fluorescent immunochromatography releaser according to claim 1 in fluorescent immunochromatography.
3. Use of the fluorescent immunochromatography releaser according to claim 1 in preparing a dry fluorescent immunochromatography reagent storage solution.
